Nuclear factor of activated T cells-regulated gene expression as predictive biomarker of personal response to calcineurin inhibitors

Therapeutic Drug Monitoring

Volumn 38, Issue 2, 2016, Pages S50-S56

  Sommerer, Claudia ^a   Giese, Thomas ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Biomarker; Calcineurin inhibitors; Gene expression; NFAT; Transplantation

Indexed keywords

BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; CYCLOSPORIN A; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; TACROLIMUS; TRANSCRIPTION FACTOR NFAT; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; DIABETES MELLITUS; DRUG MONITORING; GENE EXPRESSION REGULATION; GINGIVA HYPERPLASIA; GINGIVA OVERGROWTH; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION COMPLICATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALIGNANT NEOPLASTIC DISEASE; NEUROTOXICITY; PHARMACODYNAMIC PARAMETERS; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; BLOOD; GENE EXPRESSION; GENETICS; PROCEDURES;

BIOMARKERS; CALCINEURIN INHIBITORS; DRUG MONITORING; GENE EXPRESSION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; NFATC TRANSCRIPTION FACTORS; TACROLIMUS;

EID: 84944345916     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000234     Document Type: Review

References (38)

1. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant. 2006;6: 1111-1131.
2. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342:605-612.
3. Wieland E, Olbricht CJ, Süsal C, et al. Biomarkers as a tool for management of immunosuppression in transplant patients. Ther Drug Monit. 2010;32:560-572.
4. Maguire O, Tornatore KM, O'Loughlin KL, et al. Nuclear translocation of nuclear factor of activated T cells (NFAT) as a quantitative pharmacodynamic parameter for tacrolimus. Cytometry A. 2013;83:1096-1104.
5. Sommerer C, Giese T, Meuer S, et al. Pharmacodynamic monitoring of calcineurin inhibitor therapy: is there a clinical benefit? Nephrol Dial Transplant. 2009;24:21-27.
6. Sommerer C, Meuer S, Zeier M, et al. Calcineurin inhibitors and NFATregulated gene expression. Clin Chim Acta. 2012;413:1379-1386.
7. Giese T, Sommerer C, Zeier M, et al. Approaches towards individualized immune intervention. Dig Dis. 2010;28:45-50.
8. Fukudo M, Yano I, Katsura T, et al. A transient increase of calcineurin phosphatase activity in living-donor kidney transplant recipients with acute rejection. Drug Metab Pharmacokinet. 2010;25:411-417.
9. Halloran PF, Helms LM, Kung L, et al. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation. 1999;68: 1356-1361.
10. Stein CM, Murray JJ, Wood AJ. Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of the cyclosporine effect. Clin Chem. 1999;45:1477-1484.
11. Hartel C, Fricke L, Schumacher N, et al. Delayed cytokine mRNA expression kinetics after T-lymphocyte co-stimulation: a quantitative measure of the efficacy of cyclosporine A-based immunosuppression. Clin Chem. 2002;48:2225-2231.
12. Hartel C, Schumacher N, Fricke L, et al. Sensitivity of whole-blood T lymphocytes in individual patients to tacrolimus (FK 506): impact of interleukin-2 mRNA expression as surrogate measure of immunosuppressive effect. Clin Chem. 2004;50:141-151.
13. Fruman DA, Klee CB, Bierer BE, et al. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci U S A. 1992;89:3686-3690.
14. Giese T, Zeier M, Meuer S. Analysis of NFAT-regulated gene expression in vivo: a novel perspective for optimal individualized doses of calcineurin inhibitors. Nephrol Dial Transpl. 2004;19(suppl 4):iv55-iv60.
15. Giese T, Zeier M, Schemmer P, et al. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation. 2004;77:339-344.
16. Sommerer C, Konstandin M, Dengler T, et al. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation. 2006;82:1280-1285.
17. Sommerer C, Zeier M, Meuer S, et al. Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. Transplantation. 2010;89:1417-1423.
18. Sommerer C, Schnitzler P, Meuer S, et al. Pharmacodynamic monitoring of cyclosporine A reveals risk of opportunistic infections and malignancies in renal transplant recipients 65 years and older. Ther Drug Monit. 2011;33:694-698.
19. Konstandin MH, Sommerer C, Doesch A, et al. Pharmacodynamic cyclosporine Amonitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients. Transpl Int. 2007;20:1036-1043.
20. Sommerer C, Hartschuh W, Enk A, et al. Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients. Clin Transplant. 2008;22:549-554.
21. Dannewitz B, Kruck EM, Staehle HJ, et al. Cyclosporine-induced gingival overgrowth correlates with NFAT-regulated gene expression: a pilot study. J Clin Periodontol. 2011;38:984-991.
22. Sommerer C, Zeier M, Meuer S, et al. Monitoring of calcineurin inhibitors by NFAT-regulated gene expression in de novo renal allograft recpients. Clin Nephrol. 2015;84:165-172.
23. Billing H, Giese T, Sommerer C, et al. Pharmacodynamic monitoring of cyclosporine A by NFAT-regulated gene expression and the relationship with infectious complications in pediatric renal transplant recipients. Pediatr Transplant. 2010;14:844-851.
24. Billing H, Breil T, Schmidt J, et al. Pharmacodynamic monitoring by residual NFAT-regulated gene expression in stable pediatric liver transplant recipients. Pediatr Transplant. 2012;16:187-194.
25. Zahn A, Schott N, Hinz U, et al. Immunomonitoring of nuclear factor of activated T cells-regulated gene expression: the first clinical trial in liver allograft recipients. Liver Transplant. 2011;17:466-473.
26. Herden U, Kromminga A, Hagel C, et al. Monitoring of nuclear factor of activated T-cell regulated gene expression in de novo and long-term liver transplant recipients treated with cyclosporine A. Ther Drug Monit. 2011;33:185-191.
27. Steinebrunner N, Sandig C, Sommerer C, et al. Pharmacodynamic monitoring of nuclear factor of activated T-cell regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitor in the course of time and correlation with acute rejection episodes-a prospective study. Ann Transplant. 2014;19:32-40.
28. Steinebrunner N, Sandig C, Sommerer C, et al. Reduced residual gene expression of nuclear factor of activated T cells-regulated genes correlates with the risk of cytomegalovirus infection after liver transplantation. Transpl Infect Dis. 2014;16:379-386.
29. Sommerer C, Giese T, Schmidt J, et al. Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression. Transplantation. 2008;85:15-21.
30. Sommerer C, Beimler J, Meuer S, et al. Monitoring of NFAT-regulated gene expression for safe tapering of CNI immunosuppression in BK virus positive renal transplant patients. J Am Soc Nephrol. 2007;18:1000. Abstract #4003.
31. Sommerer C, Schaier M, Morath C, et al. The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial. Trials. 2014;15:489.
32. Sommerer C, Zeier M, Czock D, et al. Pharmacodynamic disparities in tacrolimus treated patients developing CMV viremia. Ther Drug Monit. 2011;33:373-379.
33. Sommerer C, Baghdadi J, Theissing T, et al. NFAT-regulated gene expression as biomarker to detect patients on risk of BK-replication. Transplant Infect Dis. Submitted for publication.
34. Kung L, Halloran PF. Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. Transplantation. 2000;70:327-335.
35. van Rossum HH, de Fijter JW, van Pelt J. Pharmacodynamic monitoring of calcineurin inhibition therapy: principles, performance, and perspectives. Ther Drug Monit. 2010;32:3-10.
36. Fukudo M, Yano I, Masuda S, et al. Distinct inhibitory effects of tacrolimus and cyclosporin A on calcineurin phosphatase activity. J Pharmacol Exp Ther. 2005;312:816-825.
37. Derveaux S, Vandesompele J, Hellemans J. How to do successful gene expression analysis using real-time PCR. Methods. 2010;50: 227-230.
38. Billing H, Sommerer C, Giese T, et al. Increased cyclosporin a sensitivity in vivo in pediatric renal transplant recipients compared with adults. Ther Drug Monit. 2012;34:554-560.